I am not a PUMPER or a paid contractor of ACTC. I am simply an investor. I have been an investor with ACTC for over 2 years. I have been up and I have been down. I own a lot of shares.... And I plan to keep them all.
I have invested in ACTC for 2 reasons and only 2 reasons:
1) I believe that Robert Lanza is a genious who will change both the field of medicine and the world we live in in a fundamental way. 2) I want to make a lot of money.
I have been fortunate enough to find this stock and discover this man. It is that simple. I will be passionate about this company and this stock until I am the beneficiary of their technology, their upside and their succerss. In the interim, I urge all of ACTC's true investors to stay the course and to filter out the lies, libel and slander that is foisted on us and this board by motor mouthing short sellers.
This board is like a bathroom where juvenile deliquents that can barely form a sentence write on the walls whatever slime that comes to mind under the pretense that they have the right to talk garbage about visionaries.
Go away you short sellers. Find another bathroom to hangout in.
the money is not in blindness or the ability to cure blindness. Hepatology:Morbidity and mortality from cirrhosis is increasing rapidly in the Western world. Currently the only effective treatment is liver transplantation, an increasingly limited and expensive resource. Consequently, there has been great hope that stem cells may offer new therapeutic approaches in the management of liver disease. In this review we critically appraise the 11 published clinical studies of bone marrow stem cells in liver disease, and focus on the unresolved issues regarding their role. We outline the different mechanisms by which stem cells may impact on liver disease, as well as highlight the importance of the type of stem cell chosen. There are multiple different stem cell populations that have, in rodent studies, been shown to have differing effects on liver regeneration and fibrogenesis/degradation. Thus, choice of cell should reflect the desired or expected mechanism of action. The importance, and methods, of studying the fate of stem cells infused in clinical studies is emphasized as we seek to translate observations in rodents into the clinical setting. Finally, we discuss which cohorts of patients with liver disease would benefit from stem cell therapy, as well as establish minimum criteria for future clinical trials of stem cells.